Literature DB >> 7232458

Morphine differentially affects ventral tegmental and substantia nigra brain reward thresholds.

J M Nazzaro, T F Seeger, E L Gardner.   

Abstract

In order to differentiate the roles of the nigrostriatal and mesolimbic-mesocortical dopamine systems in the action of opiates on dopaminergically mediated intracranial self-stimulation (ICSS), the effects of chronic morphine administration and acute naloxone administration on ICSS were tested in rats with electrode placements in the substantia nigra pars compacta (A-9) and the ventral tegmentum (A-10). Acute morphine (5.0 mg/kg SC) did not affect ICSS thresholds of rats with electrodes in the A-9 nucleus when tested 1, 3, 5, and 23 hours after administration. With repeated daily administration, though, these animals showed increases in thresholds which grew progressively larger with each day of morphine treatment. This threshold elevation was not reversed by naloxone given 0.5 hour after the final morphine treatment on the fifth day. In contrast, acute morphine significantly lowered self-stimulation thresholds in rats with A-10 placements. Tolerance to this facilitatory effect was evident with chronic administration. Naloxone attentuated the lowering of threshold caused by opiate administration in these A-10 animals. The present data suggest a specificity of action of opiates on different brain systems subserving reward and reinforcement. These findings also suggest that the mesolimbic-mesocortical system may play an important role in mediating the rewarding properties of morphine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7232458     DOI: 10.1016/0091-3057(81)90398-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  14 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

Review 2.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

Review 3.  Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.

Authors:  Sarah C Akerman; Mary F Brunette; Alan I Green; Daisy J Goodman; Heather B Blunt; Sarah H Heil
Journal:  J Subst Abuse Treat       Date:  2014-12-22

Review 4.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

5.  Acute morphine lowers brain stimulation reward thresholds in rats with depressed or elevated response rates.

Authors:  B Hine; M Lopez
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Effects of morphine and naloxone on thresholds of ventral tegmental electrical self-stimulation.

Authors:  L van Wolfswinkel; J M van Ree
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

7.  Opioid peptides and self-stimulation of the medial prefrontal cortex in the rat.

Authors:  S G Shaw; F Vives; F Mora
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Brain site variations in effects of morphine on electrical self-stimulation.

Authors:  W T Nelson; S S Steiner; M Brutus; R Farrell; S J Ellman
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system.

Authors:  C Spyraki; H C Fibiger; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Autoantibodies against opioid or glutamate receptors are associated with changes in morphine reward and physical dependence in mice.

Authors:  Francesca Capone; Walter Adriani; Maria Shumilina; Galina Izykenova; Oleg Granstrem; Svetlana Dambinova; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2008-02-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.